Journal Article

Efficacy of Cystic Fibrosis Transmembrane Regulator Corrector C17 in Beta-Sarcoglycanopathy—Assessment of Patient’s Primary Myotubes

Benetollo, Alberto, Akyurek, Eylem Emek, Sacchetto, Roberta, Sandonà, Dorianna, Carotti, Marcello, Dalla Barba, Francesco, Scano, Martina

2024

Overview

Limb–girdle muscular dystrophy type 2E/R4 (LGMD2E/R4) is a rare disease that currently has no cure. It is caused by defects in the SGCB gene, mainly missense mutations, which cause the impairment of the sarcoglycan complex, membrane fragility, and progressive muscle degeneration. Here, we studied the fate of some β-sarcoglycan (β-SG) missense mutants, confirming that, like α-SG missense mutants, they are targeted for degradation through the ubiquitin–proteasome system. These data, collected using HEK-293 cells expressing either the I119F- or Y184C mutants of β-SG, were subsequently confirmed in primary myotubes derived from an LGMD2E/R4 patient carrying a homozygous I92T mutation. The knowledge that β-SG with an amino acid substitution shares a pathway of degradation with α-SG mutants, allowed us to explore the pharmacological approach successfully tested in LGMD2D/R3. Several CFTR correctors, particularly corrector C17, preserved β-SG mutants from degradation and promoted localization at the sarcolemma of the entire SG complex. The presence of the complex, despite containing a mutated subunit, improved sarcolemma integrity, as evidenced by the reduced creatine kinase release from myotubes under hypoosmotic stress. These results suggest that β-SG missense mutants undergo proteasomal degradation as α-SG mutants, and that CFTR correctors, particularly C17, may be used as a potential therapeutic option for recovering and stabilizing the SG complex in patients with sarcoglycanopathies.

• Publisher: MDPI AG
• Subject: Amino acids / Biopsy / Cystic fibrosis / Cystic Fibrosis Transmembrane Conductance Regulator - genetics / Cystic Fibrosis Transmembrane Conductance Regulator - metabolism / Drug therapy / Genetic aspects / Genotype & phenotype / Health aspects / HEK293 Cells / Humans / Localization / Membrane proteins / Muscle Fibers, Skeletal - metabolism / Muscle Fibers, Skeletal - pathology / Muscular Dystrophies, Limb-Girdle - genetics / Muscular Dystrophies, Limb-Girdle - metabolism / Muscular Dystrophies, Limb-Girdle - pathology / Muscular dystrophy / Mutation / Mutation, Missense / Physiological aspects / Proteasome Endopeptidase Complex - metabolism / Proteins / Proteolysis / Quality control / Sarcoglycanopathies - genetics / Sarcoglycanopathies - metabolism / Sarcoglycanopathies - pathology / Sarcoglycans - genetics / Sarcoglycans - metabolism / Sarcolemma - metabolism